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Abstract
Background: Lower urinary tract symptoms (LUTS) can relate to urinary storage or voiding. In men, the prevalence
and severity of LUTS increases with age, with a significant impact on quality of life. The majority of men
presenting with LUTS are managed by their general practitioner (GP) in the first instance, with conservative
therapies recommended as the initial treatment. However, the provision of conservative therapies in primary
care is variable and can be time and resource limited. GPs require practical resources to enhance patient
engagement with such interventions. TRIUMPH aims to determine whether a standardised and manualised care
intervention delivered in primary care achieves superior symptomatic outcome for LUTS versus usual care.
Methods/design: TRIUMPH is a two-arm, cluster randomised controlled trial (RCT) being conducted in 30 National
Health Service (NHS) general practices in England. The TRIUMPH intervention comprises a standardised LUTS advice
booklet developed for the trial with patient and healthcare professional (HCP) consultation. The booklet is delivered to
patients by nurses/healthcare assistants following assessment of their urinary symptoms. Patients are directed to
relevant sections of the booklet, providing the manualised element of the intervention. To encourage adherence, HCPs
provide follow-up contacts over 12 weeks. Practices are randomised 1:1 to either deliver the TRIUMPH intervention or a
usual care pathway. The patient-reported International Prostate Symptom Score (IPSS) at 12months post consent is the
primary outcome. Secondary outcomes include cost-effectiveness, patient-reported outcomes on LUTS, quality of life,
and patient and HCP acceptability and experience of the intervention. Primary analyses will be conducted on an
intention-to-treat basis.
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Discussion: It is unclear whether conservative therapies for male LUTS are effectively delivered in primary care using
current approaches. This can lead to men being inappropriately referred to secondary care or experiencing persistent
symptoms. Primary care, therefore, holds the key to effective treatment for these men. The TRIUMPH intervention,
through its standardised and manualised approach, has been developed to support GP practices in delivering effective
conservative care. This pragmatic, cluster RCT should provide robust evidence in a primary-care setting to inform future
guidelines.
Trial registration: ISCRTN registry, ID: ISRCTN11669964. Registered on 12 April 2018.
Keywords: TRIUMPH, Lower urinary tract symptoms, Cluster randomised controlled trial, Primary care, International
Prostate Symptom Score
Background
For many men, lower urinary tract symptoms (LUTS)
significantly affect quality of life (QoL) , work and other
activities; such problematic LUTS are described as
‘bothersome’ according to the impact on the patient [1].
Since the risk of LUTS increases with age, the number
of patients affected is likely to increase by almost 50% by
the year 2025, in line with the ageing population [2].
LUTS can relate to storage (increased urinary fre-
quency, nocturia, urgency, incontinence), voiding (slow
stream, hesitancy, straining) or post-voiding (post-void-
ing dribble, sensation of incomplete emptying) symp-
toms. Men usually present with a range of LUTS.
Particularly high-impact LUTS for men are; urgency/ur-
gency incontinence, post-micturition dribble, nocturia
and increased urinary frequency [3–5]. Disease-specific,
health-related QoL measures are significantly worse in
men with higher symptom frequency and severity ratings
than in men with low symptom frequency and severity
ratings in population-based studies [6]. LUTS can be
caused by prostate enlargement leading to obstruction
or bladder dysfunction, but are also influenced by men’s
lifestyle and habits, such as overall fluid and caffeine
intake.
The UK National Institute of Health and Care Excel-
lence (NICE) Clinical Guideline 97 [7] recommends that
men receive key assessments (exclusion of serious med-
ical conditions, malignancy and urinary tract infection),
and assessment of the impact of their LUTS symptoms
(storage/voiding/post voiding). Conservative treatment
measures (fluid advice, bladder training, urethral com-
pression and release, and pelvic-floor muscle exercises)
are then recommended as initial interventions [7]. On
the basis of a systematic review of assessment and ther-
apy of male LUTS, the European Association of Urology
(EAU) Guidelines on Male LUTS for secondary care
stated that categorising precise symptoms (storage/
voiding/post voiding) is an expectation of urological
practice, and also recommended conservative treat-
ment measures [8, 9].
The assessment expectations described in these guide-
lines are relatively time-consuming for a 10-min general
practitioner (GP) consultation, with little resource to
support the conservative approach. Thus, men may
undergo limited assessment mainly to exclude serious
underlying conditions. Ineffective delivery of conserva-
tive measures in primary care can mean that men simply
receive a prescription of medication to treat the prostate,
are inappropriately referred to secondary care or endure
persistent symptoms. In a Quality and Productivity
Proven Case Study the costs saved by reducing inappro-
priate referrals to secondary care for male LUTS were
£21,652 per 100,000 population [10].
The evidence to support conservative interventions is
limited. The Cochrane review on lifestyle interventions
for the treatment of urinary incontinence in adults [11]
suggested that there is insufficient evidence to justify
fluid advice for treatment of urgency incontinence. How-
ever, an NHS Evidence Update indicated that self-man-
agement may have a role in the treatment of LUTS [12],
citing a post-hoc analysis [13] of a single-centre rando-
mised controlled trial (RCT) [14] of 140 men with LUTS
assigned to a self-management programme plus standard
care or standard care alone. Men assigned to the self-
management programme reported better voided vol-
umes, reduced daytime frequency and nocturia. The
study had a relatively small patient population and was
conducted in a single tertiary-treatment centre. The
study did not affect NICE Clinical Guideline 97 [7] and
indicated that a multicentre RCT would be needed to
see if these results could be replicated in everyday clin-
ical practice.
The aim of the TRIUMPH trial is to establish the clin-
ical and cost-effectiveness of conservative therapies to
treat men with LUTS through a manualised and standar-
dised resource for primary care. The study has the po-
tential merit of exploring the means to introduce self-
management of LUTS into clinical care, and the pri-
mary-care setting reflects an NHS priority to reduce
hospital referrals.
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Methods/design
Aims and objectives
The key aim of this research is to determine whether a
standardised and manualised care intervention achieves
superior symptomatic outcome compared with usual
care for male LUTS, with a primary outcome of overall
International Prostate Symptom Score (IPSS) measured
12months after consent, in a primary-care setting.
Secondary objectives are to compare the two trial arms
with regard to:
1. Disease-specific QoL
2. Symptomatic outcomes
3. Cost-effectiveness
4. Relative harms
5. Use of NHS resources
6. Overall QoL and general health
7. Acceptability of assessment and provision of care
8. Patients’ perception of their LUTS condition
Trial design
This is a pragmatic, two-arm, cluster RCT randomis-
ing GP practices 1:1 between a care pathway based
on a standardised and manualised care intervention
(intervention arm) and one based on usual care (com-
parator arm) for men with LUTS. The study flow dia-
gram is provided in Fig. 1 and the Standard Protocol
Items: Recommendations for Interventional Trials
(SPIRIT) Checklist in Additional file 1. The trial de-
sign included an internal pilot recruitment phase of 4
months’ duration, primarily to verify that recruitment
was possible before progression to the main phase of
the trial.
The study is powered to detect a clinical improve-
ment in overall IPSS score of 2. IPSS is a patient-re-
ported questionnaire and will be completed at
baseline, and at 6 and 12 months after consent, with
the primary endpoint at 12 months post consent. Sec-
ondary outcomes are collected by questionnaire at 6
and 12 months and extracted from primary-care med-
ical records at 12 months. All participants will be pro-
vided with study progress updates at 3 and 9 months
via a newsletter to maintain engagement with the trial
and encourage response rates of follow-up question-
naires. The newsletter does not provide any detail on
the TRIUMPH intervention.
Setting
Thirty GP practices were recruited within 12 CCGs
across the West of England and Wessex Clinical
Research Network (CRN) regions in the UK. Participants
are identified and recruited from these practices.
Recruitment of GP practices
The CRNs invited GP practices to express an interest in
taking part in the study. In order to achieve a balanced
range of practices, the following factors were considered:
 Number of potentially eligible patients, on conduct
of a preliminary database search
 Patient list size
 Deprivation score (calculated using the GP practice
postcode)
 Preference for intervention delivery (practice staff or
trial research nurses (RNs))
 Treatment-room space available for intervention
delivery
Selected sites underwent site initiation training. An in-
ternal pilot phase was conducted with eight initial sites
over a period of 4 months before the main phase of the
trial.
Participants
This is a pragmatic trial, which includes all adult men
who consider themselves to have bothersome LUTS,
presenting to primary care within the past 5 years, with
at least one symptom of LUTS. Only men with prevalent
cases of LUTS are included in the trial. Detailed inclu-
sion and exclusion criteria are provided in Table 1.
Patient screening and invitation
The process of patient invitation and screening is de-
tailed below:
1. GP practices conduct a single database search to
identify potentially eligible patients. The database
search was developed specifically for the trial, based
on the trial inclusion and exclusion criteria
(Table 2) for both EMIS and SystmOne patient
administration systems used in primary-care sites in
both CRN regions
2. The patient list identified by the search is manually
screened by GPs at the site against patient’s records
using the eligibility criteria listed in Table 2,
including criteria which could not be fully included
in the search, such as lack of capacity to consent,
and referral or review by secondary care
3. A de-identified screening log populated with
eligibility codes for all patients identified from the
search is sent to the central trial team
4. Invitation letters, with Patient Information Leaflets
(PIL) and Expression of Interest (EOI) forms are
mailed out to eligible patients by practices using an
approved third party (Docmail – a secure service
which automates sending invitation letters to
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Fig. 1 Study flow diagram
Table 1 Patient selection criteria
Patient selection criteria
Inclusions Adult men above the age of 18 years who have bothersome lower urinary tract symptoms (LUTS)
Exclusions • Lack of capacity to consent
• Unable to pass urine without a catheter (indwelling or intermittent catheterisation)
• Relevant neurological disease or referral
• Undergoing urological testing for LUTS
• Currently being treated for prostate or bladder cancer
• Previous prostate surgery
• Poorly controlled diabetes mellitus
• Recently referred or currently under urology review
• Visible haematuria
• Unable to complete assessments in English
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potential participants). A single mail out is
conducted for each site
5. Interested patients complete their EOI forms online
or return paper copies by post
6. CRN nurses or clinical practitioners trained by
the trial team conduct phone calls with
interested patients. These calls are conducted
whilst blinded to the allocation of the practice
and, therefore, the patient, to avoid any bias.
Calls are conducted to confirm eligibility,
particularly the subjective criteria of whether the
patient’s LUTS is bothersome to them, ensure
patient understanding of the study, answer any
questions and confirm willingness to participate
The number of patients manually screened by sites
and included in the single mail out varied between the
pilot and main phase of the trial:
 Pilot phase: during the pilot phase of the trial
sites manually screened up to 325 potentially
eligible patients identified from their database
search, in order of NHS number. The maximum
number of patients for an individual site to
include in their invitation mail out was 150;
however, the screening allowed for the potential
of a second mail out. For sites with more than
150 eligible patients, the central study team
randomly identified the 150 patients for
invitation
 Main phase: during the main phase of the trial, sites
with more than 220 eligible patients screen up to
this number, in order of NHS number. The
maximum number of patients invited into the trial
from a single site is 220
Cluster randomisation
GP practices are the units of allocation for the two study
arms. Practices are randomised on a 1:1 basis to deliver
either the TRIUMPH intervention or continue with
usual care (control group) by a statistician blind to the
identity of practices. Randomisation is conducted after
the practices have completed their screening and invita-
tion to eligible patients. Randomisation is minimised by
centre (Bristol and Wessex), practice size (number of pa-
tients registered at the practice) and area-level
deprivation (Index of Multiple Deprivation score, IMD)
of the practice.
Patient consent
Patients deemed willing and eligible to participate in the
study by the CRN are posted a consent form and a ques-
tionnaire containing baseline measures specific to trial
arm for completion (Fig. 2). However, patients are
blinded to their allocation until their completed ques-
tionnaire and consent form are received.
Withdrawal
Participants remain in the trial unless they choose to
withdraw, or if they are unable to continue. Patients may
Table 2 Database search and manual screening criteria
Database search
Inclusion criteria
Adult men (age ≥ 18 years) Male > 18 years old
Bothersome LUTS LUTS; BPH; nocturia; urinary symptoms; prostatism; overactive bladder (within last 5 years)
Exclusion criteria
Lack of capacity to consent Dementia; learning disability; psychosis; schizophrenia (ever) – additional check in manual
screen for any other indication of lack of capacity
Unable to pass urine without a catheter (indwelling
or intermittent catheterisation)
Catheter code (in last 3 months)
Relevant neurological disease or referral Dementia; Parkinson’s; MS; previous stroke (ever)
Additional check in manual screen for any other neurological disease/referral that may
affect LUTS
Undergoing urological testing for LUTS Reviewed during manual screen only
Currently being treated for prostate or bladder
cancer
Prostate or bladder cancer (ever)
Previous prostate surgery TURP; prostatectomy; BNI (ever)
Poorly controlled diabetes mellitus Latest HbA1c > 65
Recently referred or currently under urology review Reviewed during manual screen only
Visible haematuria Visible haematuria (in last 6 months)
Unable to complete assessments in English Reviewed during manual screen only
BNI bladder neck incision, BPH benign prostatic hypertrophy, HbA1c glycosylated haemoglobin, LUTS lower urinary tract symptoms, MS multiple sclerosis
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withdraw fully from the study or from specific elements
without giving a reason. Any data collected up until the
point of withdrawal are retained. Participants are in-
formed of this in the PIL prior to consent.
Blinding
Two statisticians are supporting this trial. The senior
statistician co-applicant is blinded throughout the trial.
The trial statistician will perform all disaggregated ana-
lyses according to a pre-specified statistical analysis plan
and attends closed Data Monitoring Committee (DMC)
meetings as required. The CRN support team is blinded
whilst conducting patient eligibility calls to minimise
selection and recruitment bias. Patients are blinded to
their allocation until their completed baseline questionnaire
and consent form are received. The trial health economist
will remain blinded until completion of the cleaning of the
resource-use data, and will perform all disaggregated ana-
lyses according to a pre-specified health economics analysis
plan. The remaining members of the study team remain
blinded to aggregate data only.
Interventions
TRIUMPH intervention arm
LUTS presentations are typically a composite of different
symptom combinations. The TRIUMPH intervention
targets component symptoms with specific educational
information and active management. This is provided in
a standardised way in the form of a booklet which the
patients can read in their own time to encourage take-
STUDY PERIOD
Screening
Patient
Enrolment
Post-enrolment
TIMEPOINT Pre-consent Baseline Visit 1
1
week
4
weeks
12
weeks
6
months
12
months
Practice Eligibility
screen
X
Practice Allocation X
CRN Eligibility
Screen X
Informed consent X
INTERVENTIONS:
Usual care
HCP-delivered
booklet X
1
Follow up nurse
contacts X
1 X1 X1
ASSESSMENTS:
Case report form X1 X1 X1 X1 X
ICIQ Bladder diary X1
IPSS X X X
ICIQ-UI-SF X X X
B-IPQ X X X
EQ-5D-5L X X X
Interviews
GP medical record
review X
Fig. 2 Schedule of enrolment, interventions and assessments
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up of the information. However, the intervention also
provides manualised care, with a healthcare professional
(HCP) using basic assessments and discussion with the
patient to direct them to the most applicable informa-
tion in the booklet. The discussion considers their
personal circumstances, symptom needs, bothersome-
ness of these symptoms and impact on QoL. The TRI-
UMPH intervention arm, therefore, offers standardised
and manualised care according to the symptomatic pres-
entation of the individual patients.
The TRIUMPH intervention booklet underwent
sequential development in multiple iterations and
consultations involving patients, HCPs and health
psychologists.
Details of the TRIUMPH intervention are provided
below:
1. The intervention is delivered by a trained HCP;
either a GP practice clinical nurse, RN or
healthcare assistant (HCA), or dedicated trial RN
depending on site preference
2. The HCP reviews the patient’s baseline urinary
symptoms utilising their completed IPSS, The
International Consultation on Incontinence
Questionnaire Urinary Incontinence-Short Form
(ICIQ-UI-SF) and ICIQ bladder diary
3. The participant attends for a single intervention
visit, during which the HCP discusses their
individual symptoms and level of bother. The HCPs
are provided with a decision tool to assist them in
tailoring the treatment for each patient at their
intervention visit based on their symptoms
4. The HCP provides the patient with the illustrated
booklet of written information ‘Helping you to take
control of your waterworks’. The sections included
are:
 Advice on drinks and liquid intake
 Advice on controlling an urgent need to urinate
 Exercising the muscles between the legs (pelvic
floor) to help stop bladder leakage
 Advice on emptying the bladder as completely as
possible
 Advice on getting rid of the last drops of urine
 Reducing sleep disturbance caused by needing to
urinate
The booklet is water-resistant and able to lie flat when
open, which is useful when potentially used when in the
bathroom. Pictorial representations were used for clarity
and avoid the use of potentially embarrassing images.
1. The delivery of the booklet is personalised by the
HCP who directs the patient to the relevant
sections of the booklet and, therefore, steps to take
personally. A maximum of three sections are
recommended to each patient and tabbed with
discreet stickers. Where more than three relevant
sections are identified as relevant to a patient, the
three most bothersome are chosen. The choice of a
maximum of three sections was guided by Patient
and Public Involvement (PPI) consultation on what
they considered to be a manageable level of advice
to follow
2. To encourage and gauge adherence to the
intervention, regular patient contact is provided
following the initial face-to-face appointment.
Follow-up contacts are conducted by phone at 1
week, and then by phone, email or text at 4 and 12
weeks according to patient preference. Patients
retain the intervention booklet at the end of this
period
The TRIUMPH intervention, therefore, aims to ad-
dress key limitations in the current provision of care to
men with LUTS in primary care through the use of
symptom scores and bladder diaries to effectively diag-
nose specific LUTS symptoms, the provision of effective
written materials, and training of RNs/HCAs in the in-
terpretation of symptom scores and use of the Theory of
Planned Behaviour to support self-management [15].
Patients in the intervention arm continue to receive
usual care from their GP for their LUTS where neces-
sary and details of this will be collected at 12 months.
Intervention training
The chief investigator (CI) developed the training and
delivered this to the TRIUMPH study RNs. Materials
were developed to support the training as well as the
intervention visits. The TRIUMPH nurses attended GP
practices to deliver training to practice nurses or HCAs.
Training included examples of bladder diaries and how
primary-care staff should interpret them for the purpose
of the trial. Nurses were trained on the responses to the
questionnaires and which sections of the booklet they
should direct the participant to. This was supported by a
checklist developed specifically for the study. Monthly
teleconferences were held between the nurses/HCAs
delivering the intervention and the trial managers for
ongoing support, resolution of queries and sharing of
experience.
Usual-care arm
Usual care (the comparator arm for TRIUMPH) in this
study requests sites to continue to follow their standard
local practice for trial patients. Usual care was chosen as
the comparator for the study to reflect the actual care
provided by control-arm GP practices rather than the
National Institute for Health and Care Excellence
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(NICE) guidance which may be variably implemented.
The qualitative aspect of this trial will explore what
usual care looks like for a sample of comparator and
intervention practices.
Post-trial care
Following the end of the trial, patients in the interven-
tion arm will be able to retain the booklet provided, and
patients in the control arm will be provided with the
booklet alongside a summary of the results of the trial.
Their LUTS care will be the responsibility of their GP
throughout the trial and after they have completed the
TRIUMPH study at 12 months.
Outcome measures
The primary outcome measure is the patient-reported
IPSS at 12 months after consent. The IPSS is validated,
extensively tested in LUTS research, and widely
employed in urology services. The ICIQ-UI-SF supple-
ments the IPSS with the inclusion of incontinence.
Secondary outcome measures:
 LUTS-specific QoL at 6 and 12 months (IPSS QoL)
 Symptoms scores at 6 months (IPSS overall score)
and 6 and 12months (ICIQ-UI-SF)
 Cost-effectiveness analyses from an NHS perspective
with a 12-month time horizon. The EuroQol
Group’s five-dimension health status questionnaire
(EQ-5D-5 L) will be used to calculate quality-
adjusted life years (QALYs)
 Number of adverse events (e.g. infection, urinary
retention)
 Number of GP consultations
 Number of referrals to secondary care
 Overall QoL measured by the EQ-5D-5 L
 A qualitative element of the research study will
evaluate patient experiences of the intervention
 Patient perception of their LUTS using the Brief
Illness Perception Questionnaire (B-IPQ)
Assessment and follow-up
The components and timing of follow-up measures are
shown in Fig. 2.
Clinical and patient-reported outcomes
All participants complete self-reported outcome mea-
sures in the form of questionnaires (IPSS, ICIQ-UI-SF,
EQ-5D-5 L and B-IPQ) at baseline (postal), 6 and 12
months (postal, online or phone) post enrolment. Partic-
ipants are sent one reminder to return their baseline ma-
terials, and up to three reminders to return their 6- and
12-month questionnaires.
Data extraction of GP records at 12 months will be
used to collect the secondary outcomes and healthcare
resource measures including GP consultations, adverse
events, referrals to secondary care and medications.
Study-designed Case Report Forms (CRFs) are com-
pleted for the intervention arm only, at the intervention
visit and during the 12-week treatment phase to collect
details of the booklet sections advised to the patient, and
feedback on the booklet.
Economic data collection
Data from the EQ-5D-5 L will be used to calculate qual-
ity-adjusted life years (QALYs). Information from the
GP record data extraction will provide details of health-
care resource use for the economic evaluation. The
intervention-arm CRFs will collect resources related to
delivery of the intervention (e.g. HCP time).
Qualitative data collection
A qualitative component is included to evaluate patients’
attitudes to, and experiences of, standardised and man-
ualised care interventions for men with LUTS, including
patients within the control group and their LUTS expe-
riences. Help-seeking drivers and previous experiences
of LUTS management will also be explored. HCP views
on the interventions will be explored as well as facets of
trial participation. A small group of patients who decline
to participate in TRIUMPH will be interviewed to ex-
plore their reasons for not participating and identify po-
tential areas of improvement in the trial design.
Interviews will be semi-structured and follow a topic
guide which will encourage participants to discuss their
perspectives with regard to the aims above. They will be
conducted during the pilot phase (control group ex-
cluded from this stage to explore acceptability of the
intervention) and main phase with study participants. In-
terviews will focus on LUTS experiences and expecta-
tions from treatment at baseline. At 6–12months
following the treatment period, follow-up interviews will
focus on outcomes and the experience of the treatments
or interventions received in both groups. Clinicians will
be interviewed to explore their perspectives on LUTS
management, their perspectives on the intervention and
standard care and their experience of being involved in
the trial.
Interviews will be audio-recorded, transcribed verba-
tim and uploaded into a qualitative software package
(NVivo10) to aid data management. Thematic content
analysis will be undertaken on an ongoing basis in an it-
erative manner. Interviews will continue until data satur-
ation is achieved in addition to ensuring representation
of the different features of the trial and participants,
such as age, presenting symptoms, geographical location
and usage of different sections of the standardised
booklet.
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Trial oversight
The study is supervised by a Trial Management Group
(TMG) consisting of grant holders and other relevant
trial delivery staff. A Trial Steering Committee (TSC)
oversees the progress of the trial, comprising of an inde-
pendent Chair and three other independent members,
including a PPI representative, and the CI. A DMC
monitors accumulating trial data for quality, complete-
ness and patient safety, and comprises an independent
Chair and two other independent members, and the CI.
All serious adverse events (SAEs) are recorded and noti-
fied as appropriate to the relevant authorities.
PPI
Extensive PPI was undertaken to develop the TRIUMPH
intervention booklet, and also provided input on patient-
facing materials and questionnaires. Patient representa-
tives on both the TMG and TSC provide ongoing guid-
ance for the trial, and with one patient as a co-applicant
on the grant application, PPI input into the study has
been ongoing since its conception. A wider Patient
Advisory Group (PAG) also provide additional support.
Data management and confidentiality
Study data are collected and managed using REDCap
[16] hosted at the University of Bristol. The database in-
corporates data entry and validation rules to reduce
data-entry errors, and management functions to facilitate
auditing and data-quality assurance. The database sys-
tem will protect patient information in line with the data
protection legislation. Trial staff will ensure that partici-
pants’ anonymity is maintained through protective and
secure handling and storage of patient information. The
CI will have access to, and act as custodian of, the full
dataset.
Dissemination
The results of the study will be published in the aca-
demic press and all participants will be offered a lay
summary of the main findings of the study. The trial will
also be presented at national and international confer-
ences. The results will be disseminated to the primary-
care and urology communities through the relevant
bodies.
Sample size
A scoping search was conducted with local practices
within the host CCG to gain a sense of the likely number
of patients available on their practice lists based on the
trial inclusion and exclusion criteria. This search sug-
gested that an average-sized practice (7500) might iden-
tify 100 patients. Assuming that 50% of these patients
will be eligible and 70% consent, each practice would
consent 35 eligible patients. Our estimates of eligibility
rates, consent and loss-to-follow-up are conservative and
based on our experience running pragmatic trials.
This study is powered to detect a mean change of 2
points in IPSS scores at 12 months. The recognised
minimum important difference in IPSS scores is 3 in
men with LUTS generally [17], but a smaller difference
was chosen in consultation with patient input when de-
signing the TRIUMPH study because the study expects
to include some men who have only one symptom re-
quiring treatment (e.g. nocturia). We originally esti-
mated that 840 patients are needed from at least 24
practices to detect a difference in IPSS scores of 2 (com-
mon standard deviation (SD) of 5; in line with the as-
sumptions made in the UPSTREAM study [3]) with 90%
power and significance level 5%. This estimate incorpo-
rated a design effect to account for clustering of effects
in practices which assumed that practices will be able to
recruit 35 patients each and that the intra-class correl-
ation between practices would be 0.05 – an estimate in
line with results from other primary-care studies [18].
We allowed for up to 30% of men being lost to fol-
low-up.
During the pilot phase of the trial it became clear that
the number of patients recruited by practices varied and
that many were not recruiting the estimated 35 patients.
Exploration of the recruitment data at practices that
completed their mail outs and estimates for those to be
opened suggested that 30 practices would be required to
detect our stated effect size with 90% power assuming a
mean practice size of 26 and coefficient of variation in
practice size of 0.26.
Statistical analysis
All analyses and reporting will be in line with Consoli-
dated Standards of Reporting Trials (CONSORT) guide-
lines and its extension for cluster randomised trials.
Primary analyses will be conducted on an intention-to-
treat (ITT) basis. A full statistical analysis plan will be
developed and agreed by the TSC prior to undertaking
analyses of the main trial.
Descriptive statistics will be used to summarise char-
acteristics of practices and patients and compare base-
line characteristics between groups (age, deprivation
based on practice location, height, weight, ethnicity and
marital status). Means and SDs will be used for continu-
ous and count outcomes or medians and interquartile
range if required for skewed data. Categorical variables
will be summarised using frequencies and proportions.
Patient-reported outcome scores based on standardised
questionnaires, including the primary outcome of LUTS
score, will be calculated based on the developers’ scoring
manuals and missing and erroneous items will be han-
dled according to these manuals.
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The primary outcome is the IPSS score collected at 12
months post baseline. It will be described in each treat-
ment group using means and SDs. Comparisons between
treatment arms will be made using a multilevel linear
model to allow for clustering within practices adjusting
for baseline IPSS scores and practice-level variables used
in the randomisation. We will explore whether there is
clustering in our primary outcome by the nurse/HCA
delivering the intervention. If present, we will account
for this in sensitivity analyses using a linear mixed
model. The underlying assumptions of this model will
be checked, and analyses adjusted accordingly.
Secondary outcomes explore LUTS, measures of QoL,
self-management, adverse events, use of LUTS medica-
tion and referrals to primary and secondary care. Con-
tinuous outcomes will be studied in the same manner as
the primary outcome using multilevel linear models to
allow for clustering within practices adjusting for base-
line measures of the outcome where available. Binary
outcomes will be studied using multilevel logistic regres-
sion models allowing for clustering within practices.
Count variables will be studied using multilevel Poisson
regression models – or negative binomial model depend-
ing on the distribution of counts – allowing for cluster-
ing within practices. All models will adjust for variables
used in the randomisation, the underlying assumptions
of the models will be checked, and analyses adjusted
accordingly.
Economic data analysis
The trial will include a formal economic evaluation
comparing the costs and cost-effectiveness of the
intervention from an NHS perspective, from baseline
to 12 months’ follow-up. The cost of the intervention
and the use of primary and secondary NHS services
by the men in relation to their bothersome LUTS will
be estimated through the collection of resource-use
data from GP records and study-designed proformas,
and will be valued using routine data and GP practice
information.
The values from EQ-5D-5 L, administered at baseline,
6 and 12months, will be transformed into utility scores
and individual QALYs will be calculated using the area-
under-the-curve approach.
Resource use (e.g. number of GP consultations) will be
calculated for each arm. Differences in costs and QALYs
between the arms will be evaluated using appropriate
regression techniques. For the primary economic ana-
lysis, cost-effectiveness will be assessed using the Net
Benefit framework over a range of values for the QALY
and will include the UK cost-effectiveness thresholds of
£20,000–30,000.
A secondary economic analysis will examine the differ-
ence in costs and IPSS score. If neither arm is dominant
(i.e. both cheaper and more effective), then an incremental
cost-effectiveness ratio (ICER) will be calculated in rela-
tion to the IPSS score. If appropriate, Seemingly Unrelated
Regressions (SUR) will be used when constructing the
ICER, to account for the potential correlation between
costs and the IPSS score.
Uncertainty for these analyses will be addressed using
cost-effectiveness acceptability curves and sensitivity
analyses.
Qualitative data analysis
Theoretical purposive (non-probability) sampling will
be used to ensure that the diverse characteristics of
the population are sampled (e.g. participants of differ-
ing ages, clinical history, duration of symptoms and
at follow-up in the intervention arm, components of
the package received and drop-out/adherence). Geo-
graphical distribution will also be factored to ensure
representation of varied practice populations [19].
Sampling and analyses will continue in iterative cycles
until no new themes are emerging and established
themes cease evolving (data saturation) [20]. It is an-
ticipated that approximately 15 participants will be re-
quired for the feasibility stage, followed by a
maximum of 30 patient interviews for both baseline
and follow-up evaluation in the intervention arm and
15 at both time points in the usual-care arm during
the main trial. Where possible we will conduct fol-
low-up interviews with the same participants as the
baseline interviews to capture reflective perspectives.
However, additional participants may be required to
ensure representativeness of the spectrum of interven-
tions delivered and those considered compliant/adher-
ent to the interventions.
A convenience sample of a maximum of 20 HCPs will
also be interviewed to capture the variability of the prac-
tice populations and both usual care and intervention
practices involved.
Analyses will be conducted by the qualitative re-
searcher on an ongoing basis in an iterative manner, ac-
cording to principles of thematic content analysis [21].
Recordings will be listened to and transcripts read and
re-read for familiarisation. Segments of text will be
‘coded’ by assigning descriptive labels. Codes will be
grouped on the basis of shared properties to create
themes and coded transcripts will then be examined and
compared to inductively refine and delineate themes
(constant comparison) [22, 23].
A subset of interviews will be independently analysed
by a second study researcher and coding discrepancies
discussed to maximise rigour and reliability. Plausibility
of data interpretation will be further discussed within
the study team throughout the analyses. Descriptive
Frost et al. Trials          (2019) 20:546 Page 10 of 12
summary accounts of the audio-recordings and inter-
views will be prepared.
Discussion
This article outlines a multicentre, pragmatic, cluster
RCT to compare standardised and manualised care
versus usual care in primary care for men with
bothersome LUTS. The aim is to determine whether
the TRIUMPH intervention achieves superior symp-
tomatic outcome compared with usual care for LUTS
in primary-care setting, based on a patient-reported
severity score (IPSS).
The internal pilot phase of the trial was successfully
completed in November 2018. One hundred and
forty-two participants were recruited in the 4-month
pilot phase period, exceeding the target of 120 partic-
ipants. Sixteen practices had formally agreed to take
part in the study during the pilot phase which, al-
though slightly short of the target of 18, was suffi-
cient for progression to the main phase of the trial.
The key changes that were made to the conduct of
the trial between the pilot phase and the main phase
of the trial were an increase in the maximum number
of patients invited by a single site from 150 to 220,
and confirmation that 30 sites would be required to
maintain the trial power calculation in light of vari-
ation in the number of patients recruited per site.
The decision was also taken to conduct only a single
invitation mail out from each site to avoid introdu-
cing any bias post randomisation. Although screening
of all patients for both mail outs would have been
conducted before randomisation, re-screening would
have been required to check patient status before a
later second mail out, when sites would have been
aware of their allocation.
This cluster randomised study should provide
evidence in an NHS setting for the male LUTS popu-
lation by using various patient-reported, clinical and
cost-effectiveness outcomes to inform future NICE
guidelines and potentially the opportunity to develop
tools specifically for primary-care HCPs when treating
this population. In the event that an HCP-led assessment
and advice selection can reduce symptom severity, GP
consultations in the future will be able to focus more on
exclusion of serious conditions and potentially place less
reliance on early drug prescription.
Trial status
The TRIUMPH study commenced site recruitment in
May 2018 and recruited the first patient on 10 July 2018.
The internal pilot phase of recruitment was conducted
over 4 months and completed on 10 November 2018.
Recruitment will be completed at the end of July 2019.
Protocol version 6.0, 4 April 2019.
Additional file
Additional file 1: TRIUMPH Standard Protocol Items: Recommendations
for Interventional Trials (SPIRIT) Checklist. (DOC 124 kb)
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